Using a patient’s own immune system to destroy cancer cells, cancer immunotherapy is currently one of the most exciting fields in cancer research. In effect, the immune system can now be retrained to reject cancer tissue, which enables more powerful treatments with fewer side effects than traditional cancer therapies.
Victoria University’s Professor Gavin Painter and Avalia Immunotherapies CEO Dr Shivali Gulab are at the forefront of this research field and will offer their thoughts on what the future holds for these treatments.
Professor Gavin Painter leads a team of researchers at Victoria University’s Ferrier Research Institute, collaborating on new cancer treatments with immunologists at the Malaghan Institute of Medical Research.
New York-based Dr Shivali Gulab received her PhD in Chemistry from Victoria University, and is now CEO of Avalia Immunotherapies. Avalia is a New Zealand-based company established to commercialise an immunotherapy platform originating from a long-term government funded research collaboration between the Ferrier Research Institute of Victoria University of Wellington and the Malaghan Institute of Medical Research.
The Wellington Club